ABVX
Abivax·NASDAQ
--
--(--)
--
--(--)
4.49 / 10
Netural
Fund flow evaluation is strong (7.82/10), with positive Small and Medium trends (0.509 and 0.518 inflow ratios) despite block-level weakness. Analyst coverage is limited but bullish: two analysts rate the stock Buy/Strong Buy, though historical win rates are low (0.0% for Morgan Stanley, 33.3% for BTIG). Recent news highlights takeover speculation from Eli Lilly and advancing therapeutic programs, supporting the positive fund flow and technical momentum.
Fund Flow Rating
Analyst RatingStrong Buy
Wall Street Opinions
Strong Buy
Strong Buy
50%
Buy
50%
Hold
0%
Sell
0%
Strong Sell
0%
Date2026-01-09
InstitutionMorgan Stanley
Times predicted3
Historical Win Rate0.0%
Is money flowing into or out of ABVX?
- ABVX holds a Bearish analyst rating, with 50% of experts assigning a Strong Buy grade. Factoring in net Outflows from order flow data, the comprehensive Sentiment Score stands at 4.49/10 (Netural).
